Sang‐We Kim - Concepedia

Author

Sang‐We Kim

Also Known As

Goran Stojanovic, HeeJong Baek, Jin-Hyoung Kang, Jung-Shin Lee, Konstantin Laktionov, Sang-We Kim, Sang-we Kim, Sang‐We Kim, Sang–We Kim

368

Publications

21.1K

Citations

H-Index

Concepts

All Affiliations

Asan Medical Center University of Ulsan Ulsan College Samsung Medical Center Sungkyunkwan University

About

Sang‐We Kim is an author at Asan Medical Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	85	8.4K
2	Health Sciences	19	33	1.1K
3	Cell Biology	6	6	178
4	Engineering	2	2	76
5	Cellular Therapies	1	1	40

Sang‐We Kim

161

Publications

20.2K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabé, New England Journal of Medicine	2019	2.8K
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, The Lancet Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment	2019	2.1K
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer Yi‐Long Wu, Masahiro Tsuboi, Jie He, New England Journal of Medicine	2020	1.7K
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung Ji‐Youn Han, Keunchil Park, Sang‐We Kim, Journal of Clinical Oncology	2012	732
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, The Lancet Oncology Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment	2020	662
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study Keunchil Park, Eric B. Haura, Natasha B. Leighl, Journal of Clinical Oncology	2021	597
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2019	594
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn, Journal of Clinical Oncology Lymphoid NeoplasiaAlk-positive NsclcMedicinePharmacologyObjective Response Rate	2017	577
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2018	568
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC David Planchard, Pasi A. Jänne, Ying Cheng, New England Journal of Medicine	2023	546

Page 1